ESF-IfW Conference on The Global Health Economy:
The Global Organisation of Biomedical Innovation:
Funding, Intellectual Property Rights, Incentives and the Diffusion of New Technology
Kiel, Germany 4-8 October 2007
Chair: Frederic M. Scherer, John F. Kennedy School of Government, Harvard University, US
Vice-Chair: M.N. Graham Dukes, University of Oslo, Norway
Website: http://www.esf.org/conferences/07247 With support from www.esf.org
"….Biomedical innovation is likely to be the most important source of future gains in quality of life and longevity worldwide and represents the socially most valuable major investment opportunity at the beginning of the 21st century.
The process of globalization has enhanced that opportunity by extending the scale at which economies of scale in the generation and diffusion of new medical knowledge and technology can be exploited. To do so more efficiently will require the reorganization of a wide variety of activities, institutions and regulations that determine how well the private incentives are aligned with the global priorities in maximizing human welfare. Particular emphasis will have to be placed on novel knowledge management systems that allow the social benefits and risks of new therapies to be predicted with greater accuracy and earlier in the development process of biomedical technologies…."
Final Programme
Friday – 5 October
Session 1: Demand, Supply, Government Funding and Private Insurance in the Global Market for Biomedical Innovation
Chair: M.N. Graham Dukes, University of Oslo, NO
Félix Lobo Universidad Carlos III de Madrid, ES
Science and Regulation – How Market Regulations Increasingly Depend on Science. The Case of the European Union
Frederic M. Scherer Harvard University, Cambridge, US
Coping with Uncertainty in Pharmaceutical Development
Charles Abraham Yankah German Heart Institute Berlin, DE
The Role of Translational Medicine in Accelerating Biomedical Innovation
Darius Lakdawalla RAND Corporation, Santa Monica, US
Can A Competitive Health Insurance Market Set Optimal Incentives for Biomedical Innovation?
Rainer Sauerborn University of Heidelberg, DE
The Optimal Financing and Organisation of Health Care in Low and Middle Income Countries
Ayesha Aftab World Health Organization, Riwalpindi, PK
Health Care Responsive Budgeting – Evolving Linkages between Public and Private Investment
Carsten M.H. Claussen Evotec Technologies GmbH, Hamburg, DE
Session 2: Intellectual Property Rights and International Trade
Chair: Frederic M. Scherer, Harvard University, US
Carlos M. Correa University of Buenos Aires, AR
Diffusion of Medical Technology and Intellectual Property Rights in Latin America
Ove Granstrand Chalmers University of Technology, Göteborg, SE
The Role of Intellectual Property Rights in Biomedical Innovation
James Love Consumer Project for Technology, Washington DC, US
Prospects for a Global Treaty to Govern Biomedical Research
Ellen ‛t Hoen Médecines Sans Frontières, Paris, FR
Access to Innovative Medicines in Poor Countries – Developing a Policy Strategy
Jayashree Watal WTO, Geneva, CH
The TRIPS Agreement and Public Health – with a Focus on the Paragraph 6 System of the Doha Declaration
Naomi Hawkins The Ethox Centre, University of Oxford, UK
The Impact of Patents on the Translation of Research into Clinical Application in the Context of Genetic Diagnostics
Daniel Maceira Center for the Study of State and Society, CEDES, Buenos Aires, AR
Pharmaceutical Product Regulation in Argentina – Organizational Structure and Comparative Performance
Kathrin Adlkofer Norgenta, Life Science Nord, Hamburg, DE
Saturday – October 6
Session 3: The Social Returns to Biomedical Research
Chair: Dietmar Harhoff, University of Munich, DE
Joseph diMasi Tufts University, Boston, UK
Trends in Post-approval Pharmaceutical R&D – Dissecting the Data on Line Extensions
Frank R. Lichtenberg Columbia University, New York, US
International Medical Technology Diffusion
Ronald J. Gilson Stanford University, US
Fostering Successful Venture Investing in Biotechnology – Lessons for Europe
Simcha Jong University College London, UK
Academic Institutions and Spin-Off Firms in the Life Sciences – Berkeley,Stanford and UCSF and the Birth of the Biotechnology Industry
Rainer Sauerborn University of Heidelberg, DE
Session 4: The Fragile State of Europe's Biomedical Industry
Chair: Michael Stolpe, Kiel Institute for the World Economy, DE
Liselotte Højgaard Rigshospitalet Copenhagen, DK, and Chair, European Medical Research Councils
Present Status and Future Strategy for Medical Research in Europe
Fabio Pammolli University of Florence, and Director, IMT Lucca Institute for Advanced Studies, IT
European Pharmaceutical Innovation and Regulatory Systems
Dietmar Harhoff University of Munich, DE
Comparing the German and the British Biotechnology Industries – Finance, Management and Regulation
Maureen McKelvey Chalmers University of Technology, Göteborg, SE
Managing Bioengineering Companies – A European Perspective
Luigi Orsenigo University of Sussex, SPRU, UK and Bocconi University, IT
Knowledge Accumulation, Regulation, and Appropriability in Europe's Pharmabiotech Industry
Koen Wiedhaup Netherlands Genomics Initiative, NL
Public and Private Sector Interaction in Promoting Biomedical Innovation
Timm-H. Jessen Bionamics GmbH, Kiel, DE
Sunday – October 7
Session 5: Health Care Institutions, Investment Incentives, and the Diffusion of Innovations
Chair: M.N. Grahem Dukes, University of Oslo, NO
Yelzhan Birtanov Institute for Healthcare Development, Almaty, KZ
Ensuring Therapeutic Advance in a Transitional Economy
Ramanan Laxminarayan Resources for the Future, Washington DC, US
Antimicrobial Drug Resistance: An Agenda for Research and Policy
Tbc Samira Humaira Habib University of Dhaka, BD
Cost-effectiveness Analysis of Medical Intervention in Patients with EarlyDetection of Diabetic Foot in a Tertiary Care Hospital in Bangladesh
Alireza Haghighi University of Oxford, Nuffield Department of Clinical Medicine, UK
The Role of Diaspora in Medical Knowledge and Technology Transfer to Developing Countries – A Network Model
Nicola Leaney Phoenix Biologix Pty Ltd, Broadway, AU
Sustainable Manufacturing for Developed Countries – How to Cooperate with Emerging Economies
Wolf Rogowski GSF National Research Centre for Environment and Health, Neuherberg, DE and University of York, UK
Key Features for Monitoring and Comparing Fourth Hurdle Institutions
Peter Zweifel Socioeconomic Institute, University of Zürich, CH
The Influence of Insurance on Biomedical Innovation
Alexander Jean Luc Coad Max-Planck-Institute of Economics, Jena, DE
The Co-Evolution of Sales Growth, Employment Growth and Growth of R&D Expenditure
Pedro Luis Sanchez Farmaindustria, Madrid, ES
Prices and Penetration of Pharmaceutical Innovations – An International Comparison
Conferences on The Global Health Economy is supported by an academic advisory council that comprises leading scholars in the fields of medicine, health economics and related sciences and a number of leading representatives from German health care finance, industry and politics.
These include
· Ulrike Beisiegel, Director of the Institute for Biochemistry and Molecular Biology at the Eppendorf Research Hospital of the University of Hamburg,
· Norbert Klusen, Chairman of the Board of Techniker Krankenkasse, Hamburg, Germany's most innovative sickness fund,
· Hellmut Körner, Secretary of State for Social Affairs, Health, and Family Policy in Schleswig-Holstein,
· Heiner Raspe, Director of the Institute for Social Medicine at the Medical University of Lübeck,
· Wolfgang Reim, former President and Chief Executive Officer of Dräger Medical AG & Co. KG, a Dräger and Siemens Company, and Member of the Board of Drägerwerk AG, Lübeck,
· Ernst Theodor Rietschel, President of the Leibniz-Gemeinschaft, one of Germany largest research organizations with an extensive research portfolio in both medicine and economics and a total of 84 autonomous research institutes,
· Stefan Schreiber, Director of the Institute for Clinical Molecular Biology at the University of Kiel and Director of the German National Genome Research Network,
· J.-Matthias Graf von der Schulenburg, Director of the Institute for Insurance Economics and Director of the Research Center for Health Economics and Health Systems Research at theUniversity of Hannover, and
· Dennis Snower, Ph.D., President of the Kiel Institute for the World Economy and Chair of the Department for Economic Theory at the University of Kiel.
* * * *
This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues. [DD/ IKM Area]
"Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members".
---------------------------------------------------------------------------------------------------
PAHO/WHO Website: http://www.paho.org/
EQUITY List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html
